VIDEO: Combination of BTK inhibitor with venetoclax shows promise in mantle cell lymphoma
In this video, Stephen M. Ansell, MD, PhD, discusses primary analysis results from the phase 3 Sympatico study.
The results, presented at ASH Annual Meeting and Exposition, showed a benefit in combining a BTK and BCL-2 inhibitor for relapsed/refractory mantle cell lymphoma, Ansell, professor of medicine in the department of hematology at Mayo Clinic, Minnesota, said.
The addition of venetoclax (Venclexta; AbbVie, Genentech) to ibrutinib (Imbruvica; Janssen, Pharmacyclics) showed benefit over ibrutinib and placebo alone, Ansell said.
"That's a study with pretty substantial follow-up showing benefit. In that Sympatico study, there was the use of both agents together for a 2-year period, and then just the BTK inhibitor thereafter — but that was clearly better than just using a BTK inhibitor," Ansell said.
Reference:
- Wang M, et al. Ibrutinib combined with venetoclax in patients with relapsed/refractory mantle cell lymphoma: Primary analysis results from the randomized phase 3 Sympatico study. Presented at: ASH Annual Meeting and Exposition, Dec. 9-12, 2023; San Diego.
Collapse
Healio Interviews
Read more about